Holen Sie sich die Stockscreener-App
4.33
5.25%
-0.24
Schlusskurs vom Vortag:
$4.57
Offen:
$4.55
24-Stunden-Volumen:
744.53K
Relative Volume:
0.66
Marktkapitalisierung:
$275.23M
Einnahmen:
$157.08M
Nettoeinkommen (Verlust:
$-70.36M
KGV:
-3.8953
EPS:
-1.1116
Netto-Cashflow:
$-71.69M
1W Leistung:
-8.07%
1M Leistung:
+11.89%
6M Leistung:
+136.61%
1J Leistung:
+174.05%
1-Tages-Spanne:
$4.155
$4.57
1-Wochen-Bereich:
$4.155
$5.06
52-Wochen-Spanne:
$1.29
$5.08
Macrogenics Inc Stock (MGNX) Company Profile
Firmenname
Macrogenics Inc
Sektor
Branche
Telefon
301-251-5172
Adresse
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
4.33 | 275.23M | 157.08M | -70.36M | -71.69M | -1.1116 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2024-11-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-31 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-05-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-04-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-03-04 | Bestätigt | BTIG Research | Buy |
| 2024-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-22 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-02-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-04 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Hochstufung | Barclays | Underweight → Overweight |
| 2020-12-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2019-12-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Guggenheim | Neutral |
| 2019-02-07 | Hochstufung | Citigroup | Sell → Buy |
| 2019-02-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-02-06 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-12-10 | Herabstufung | Raymond James | Outperform → Underperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-05-31 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-31 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
MacroGenics, Inc. 8-K SEC Filing July 2026: Company Details, Stock Info, and Key Regulatory Disclosures - Minichart
Karen Ferrante to Resign from MacroGenics' Board Effective Sept 1, 2026 - TradingView
Board member Karen Ferrante to leave MacroGenics (MGNX) board in September 2026 - Stock Titan
MacroGenics Inc highlights its oncology pipeline as investors track future catalysts - ad-hoc-news.de
MacroGenics Sells GMP Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million - Minichart
MacroGenics (NASDAQ: MGNX) nets $110.7M and gain in CDMO sale - Stock Titan
Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Mfg. Ops - Contract Pharma
Bora Pharmaceuticals completes $122.5M buy of MacroGenics manufacturing operations - megaproject.com
M55 Forecast — Price Target — Prediction for 2027 - TradingView
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing OperationsBrand Spur - Brand Spur
MacroGenics completes sale of manufacturing operations to Bora By Investing.com - Investing.com Australia
MacroGenics completes sale of manufacturing operations to Bora - Investing.com
MacroGenics sells its drug-making operations to Bora for $122.5M - Stock Titan
Bora Pharmaceuticals Completes Acquisition Of Macrogenics' Rockville Manufacturing Operations - Menafn
Macrogenics | 4: Statement of changes in beneficial ownership of securities-Director O'Brien Federica F. - Moomoo
MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2500 Growth Benchmark - marketscreener.com
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2000 Value Benchmark - marketscreener.com
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2000 Growth Benchmark - marketscreener.com
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 3000E Index - marketscreener.com
Enterprise value to revenue forward of MacroGenics, Inc. – NASDAQ:MGNX - TradingView
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 3000E Value Benchmark - marketscreener.com
Price to earnings forward of MacroGenics, Inc. – NASDAQ:MGNX - TradingView
Enterprise value to revenue forward of MacroGenics, Inc. – BOATS:MGNX - TradingView
Enterprise value to EBITDA forward of MacroGenics, Inc. – BOATS:MGNX - TradingView
Enterprise value to EBIT forward of MacroGenics, Inc. – NASDAQ:MGNX - TradingView
Enterprise value to EBIT forward of MacroGenics, Inc. – BOATS:MGNX - TradingView
Price to sales forward of MacroGenics, Inc. – NASDAQ:MGNX - TradingView
Price to book forward of MacroGenics, Inc. – BOATS:MGNX - TradingView
MGNX Forecast — Price Target — Prediction for 2027 - TradingView
MacroGenics, Inc. Actuals & Estimates (NASDAQ:MGNX) - TradingView
A1W6ND Forecast — Price Target — Prediction for 2027 - TradingView
MacroGenics Inc (MGNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MacroGenics: 'Hold' Potential Best-In-Class B7-H3 ADC And TZIELD Payment (NASDAQ:MGNX) - Seeking Alpha
MacroGenics To Receive $24.5 Million Milestone From Sanofi For TZIELD Approval - Pulse 2.0
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval - The Manila Times
MacroGenics stock rises on $24.5M Sanofi milestone payment - Investing.com
MacroGenics to receive $24.5M milestone from Sanofi on FDA approval - Investing.com Australia
MacroGenics stock rises on $24.5M Sanofi milestone payment By Investing.com - Investing.com Nigeria
Sanofi (SNY) Drives $24.5M Milestone Payment to MacroGenics - GuruFocus
MacroGenics to Receive $24.5 Million in Regulatory Milestone Payment - marketscreener.com
MacroGenics to Receive $24.5 Million Milestone Payment Following FDA Accelerated Approval of Sanofi’s TZIELD for Children with Stage 3 Type 1 Diabetes - Quiver Quantitative
Sanofi’s TZIELD approval triggers $24.5M payment to MacroGenics - Stock Titan
MacroGenics (MGNX) Gains 4.3% as Shares Test Key Resistance LevelsThrowback Trade - dars.gov.et
MacroGenics Inc (MGNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MacroGenics StockThursday technical snapshot after strong year-to-date rebound - ad-hoc-news.de
MacroGenics Inc (MGNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MacroGenics Inc (MGNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MacroGenics Inc (MGNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MacroGenics Inc (MGNX) Institutional Confidence - TradingKey
Finanzdaten der Macrogenics Inc-Aktie (MGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):